More on PTGX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $145.94 |
|
|||
| Open | $146.05 | ||||
| 52 Wk High | $24.52 | ||||
| 52 Wk Low | $10.02 | ||||
| Day High | $151.19 | ||||
| Day Low | $144.59 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 250,842 | ||||
- Protagonist Therapeutics launches $300M share repurchase program
- Protagonist Therapeutics Announces $300 Million Share Repurchase Program
- Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
- Protagonist Therapeutics (PTGX) PT Raised to $190 at BMO Capital
- Protagonist Therapeutics (PTGX) PT Raised to $170 at H.C. Wainwright
- Protagonist Therapeutics (PTGX) PT Raised to $180 at Barclays
- Citi raises Protagonist Therapeutics price target to $182
- Clear Street Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
- Jefferies on Protagonist Therapeutics (PTGX): 'well-funded for multiple high value oral peptide pipeline'
- Wolfe Research on Protagonist Therapeutics (PTGX): 'We forecast peak sales of $2.9B in 2036'
Entities mentioned with PTGX
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
